Physician profile
Shantha S Kumar
NPI 1396768958
$5,881.17
in general payments reported to CMS, 2019-2025
23 companies · $1,925 in 2025
The $1,925 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $690 · 2020: $160 · 2021: $1,583 · 2022: $393 · 2023: $566 · 2024: $564 · 2025: $1,925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,036 · Travel and Lodging: $1,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,035.54 |
| Travel and Lodging | $1,020.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,261.73 | 2021-2025 | Venaseal, Abre, Turbohawk |
| Abbott Laboratories | $657.94 | 2019-2025 | Aveir, Gallant, Dragonfly Opstar |
| Boston Scientific Corporation | $589.52 | 2019-2025 | Varithena Administration Pack, General - Vascular Intervention, Opticross |
| Ge Healthcare | $364.36 | 2024-2025 | |
| Abiomed | $221.39 | 2019-2025 | Impella |
| Medtronic Vascular, INC. | $129.79 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $124.11 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $101.56 | 2022-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $99.99 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $45.46 | 2024-2025 | Eliquis, Camzyos |
| Reflow Medical INC | $40.32 | 2025 | |
| Janssen Pharmaceuticals, INC | $37.14 | 2020-2024 | Xarelto |
| Cleerly, INC. | $35.59 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Penumbra, INC. | $23.60 | 2025 | Indigo System |
| Cordis US Corp. | $22.01 | 2025 | Mynx Control Venous |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.34 | 2025 | Jardiance |
| Medline Industries LP | $18.28 | 2025 | |
| Kestra Medical Technology Services, INC. | $18.22 | 2024 | Assure Wcd |
| Inspire Medical Systems, INC. | $16.53 | 2024 | Inspire |
| Sanofi-Aventis U.S. LLC | $15.22 | 2020 | |
| Biotronik INC. | $14.79 | 2025 | Amvia Edge |
| Organogenesis INC. | $13.02 | 2021 | |
| Pfizer INC. | $11.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shantha Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.